Premium
Association of CD204 + macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT
Author(s) -
Kawajiri Akihisa,
Kitano Shigehisa,
Maeshima Akiko Miyagi,
Inamoto Yoshihiro,
Tajima Kinuko,
Takemura Tomonari,
Tanaka Takashi,
Ito Ayumu,
Okinaka Keiji,
Kurosawa Saiko,
Kim SungWon,
Taniguchi Hirokazu,
Ogawa Chitose,
Izutsu Koji,
Yamamoto Noboru,
Fukuda Takahiro
Publication year - 2019
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13324
Subject(s) - medicine , lymphoma , gastroenterology , percentile , oncology , immunology , mathematics , statistics
Objective CD204 + tumor‐associated macrophages are associated with adverse outcomes of various malignancies. We performed a study to elucidate the role of CD204 + macrophages in allogeneic hematopoietic cell transplantation (allogeneic HCT). Methods In a total of 81 patients who received allogeneic HCT for non‐remission malignant lymphoma, immunohistochemical staining of CD204 using specimens preserved before allogeneic HCT was performed. According to the average number of CD204 + macrophages in a high‐power field, patients were categorized into three groups: low (<25th percentile), intermediate (≥25th percentile and <50th percentile), and high (≥50th percentile). Results The B‐cell lymphoma proportion was higher in the low group, while T‐cell lymphoma and adult T‐cell leukemia proportions were higher in the high group. The 3‐year overall survival (OS) was poorest in the high group; low vs intermediate vs high = 83.3% vs 43.7% vs 20.2% ( P < .01). The 3‐year cumulative incidences of relapse were significantly higher in the high group than the intermediate and low groups: 67.0% vs 38.1% vs 18.2% ( P < .01). In multivariate analyses, the numbers of CD204 + macrophages were independent risk factors of poorer OS and cumulative incidences of relapse. Conclusions CD204 + macrophages might be associated with poorer prognosis in allogeneic HCT for malignant lymphomas.